DRTech is showing strong performance. As AI-driven low-dose high-resolution technology is highly valued in the global medical and industrial sectors, securities firms' analyses predicting accelerated growth appear to be influencing the stock price.
As of 9:38 AM on the 23rd, DRTech is trading at 4,450 KRW, up 7.09% from the previous day.
DRTech is a company that manufactures X-ray detectors and systems. It is expanding its business areas through continuous research and development (R&D) investments.
Kim Hak-jun, a researcher at Kiwoom Securities, explained, "Vendorable sales are expected to increase following the passage of the Aramco quality test," and added, "Demand expansion is also anticipated from the three major shipbuilders and Doosan Enerbility." He further stated, "OEM for company S is scheduled to start from the 2nd to 3rd quarter of next year, which will newly contribute about 70% of the current sales performance."
He emphasized, "We expect performance improvement as global sales channels for dental detectors and systems are secured," and added, "With the launch of the 3D mammography system and FDA approval of the current C-arm system, results from both existing and new products are anticipated."
It is estimated that consolidated sales will reach 167.6 billion KRW and operating profit 19.4 billion KRW next year. These figures represent increases of 62.0% and 207.3%, respectively, compared to this year's estimates.
Researcher Kim introduced, "The X-ray system market, including medical and mammography systems, is estimated to be a total of 13 billion USD. It refers to devices that realize actual digital images through imaging software and parameter adjustment software." He added, "DRTech is implementing low-dose high-resolution X-ray systems using AI," and predicted, "Based on this year, it is expected to explode significantly from next year."
He analyzed, "The FDA-approved C-arm system continuously captures X-rays during procedures, making it a product that integrates low-dose high-resolution technology, and it is expected to grow into a key product in the future."
Researcher Kim emphasized, "This year marks the first year for overseas expansion of new products beyond the medical detector market," and added, "Significant performance contributions are expected from next year." He also forecasted, "Industrial detectors are targeting the Middle Eastern market with two types: curved and vendorable. After completing the Aramco quality test, full-scale expansion will begin in the second half of this year based on the Gen2 product."
He explained, "The biggest risk factor is securing personnel," and said, "In addition to the current 360 employees, there are plans to expand by 100 more from the second half of this year to the first half of next year." He added, "Rapid workforce expansion is necessary to handle the scheduled volume for production capacity increase."
Earlier, An Seong-hyun, CEO of DRTech, stated in a recent interview with the media, "It is no exaggeration to say that we have completely dominated the global dental detector market. If you sum up all the customers DRTech is discussing supply with or targeting, the global dental detector market share will approach 70%."
He continued, "We have secured at least four products that can generate profits exceeding 50 billion KRW," and added, "DRTech has developed several world-first products with algorithms and AI technology that remove noise from X-ray images, along with creative ideas."
Regarding the C-arm system, CEO An introduced that quality tests were conducted at Seoul National University Bundang Hospital, and it was evaluated as superior to the current world No. 1 product.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
